INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

Company Overview - INmune Bio Inc. is a publicly traded clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease [12] - The company has two product platforms in clinical trials: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform and the Natural Killer Cell Priming Platform [12] - The DN-TNF product platform aims to selectively neutralize soluble TNF, which is a key driver of innate immune dysfunction [12] - XPRO, the first product from the DN-TNF platform, is currently in clinical trials for treating Mild Alzheimer's disease, with plans to explore additional indications such as treatment-resistant depression and oncology [12] - The Natural Killer Cell Priming Platform includes INKmune™, which is designed to prime NK cells for cancer treatment and is currently enrolling patients in a Phase I/II trial for metastatic castrate-resistant prostate cancer [12] Upcoming Events - The company will host a conference call on August 1, 2024, at 4:30 PM EDT to discuss the results for its first quarter ended June 30, 2024, and provide a corporate update [13] - Participants can access the call via a live audio webcast and are encouraged to dial in 5 to 10 minutes before the start time [4][8] - A transcript of the call will be available approximately 24 hours after the event, with a replay accessible until August 8, 2024 [9]